Literature DB >> 8338443

Biocompatibility of leukocyte removal filters during leukocyte filtration of cardiopulmonary bypass perfusate.

Y J Gu1, R Obster, J Haan, R C Gallandat Huet, A Eijgelaar, W van Oeveren.   

Abstract

To evaluate the biocompatibility and the efficacy of leukocyte removal filters, we performed a prospective study by using the cardiopulmonary bypass perfusate taken from the heart-lung machine for 20 patients who underwent cardiac surgery and were randomly divided into four groups according to the filters used. A leukocyte removal filter was installed in the transfusion line while the perfusate was transfused to the patients. No increases of C3a, C5a, elastase, and thromboxane were found during leukocyte filtration by polyester filters (Optima, Sepacell R500, and Pall RC100). Activation of the complement cascade was observed during filtration by the cellulose acetate filter (Cellselect) although the efficacy of the Cellselect filter was evidently higher than that of the polyester filter. These results imply that polyester leukocyte filters are superior to cellulose acetate filters in terms of biocompatibility but have a reduced efficacy. An optimal leukocyte filter providing both high efficacy and biocompatibility has yet to be developed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8338443     DOI: 10.1111/j.1525-1594.1993.tb00611.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  2 in total

1.  Prolonged granulocyte activation, as well as hypoxanthine and free radical production after open heart surgery in children.

Authors:  E J Pesonen; R Korpela; M Leijala; H Sairanen; O M Pitkänen; K O Raivio; P Venge; S Andersson
Journal:  Intensive Care Med       Date:  1996-05       Impact factor: 17.440

2.  Extracorporeal tumor cell filtration during extended liver surgery: first clinical use of leukocyte depletion filters--case series.

Authors:  Karl J Oldhafer; Gregor A Stavrou; Marcello Donati; Philipp Kaudel; Nils R Frühauf
Journal:  World J Surg Oncol       Date:  2013-07-17       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.